bioRxivBioinformaticsPreprint
Integration of immunome with disease-gene network reveals common cellular mechanisms between IMIDs and drug repurposing strategies
Abhinandan Devaprasad, Timothy R. D. J. RadstakeiD, Aridaman PanditiD
Abstract
ObjectiveDevelopment and progression of immune-mediated inflammatory diseases (IMIDs) involve intricate dysregulation of the disease associated genes (DAGs) and their expressing immune cells. Due to the complex molecular mechanism, identifying the top disease associated cells (DACs) in IMIDs has been challenging. Here, we aim to identify the top DACs and DAGs to help understand the cellular mechanism involved in IMIDs and further explore therapeutic strategies. MethodUsing transcriptome profiles of 40 different immune cells, unsupervised machine learning, and disease-gene networks, we constructed the Disease-gene IMmune cell Expression (DIME) network, and identified top DACs and DAGs of 12 phenotypically different IMIDs. We compared the DIME networks of IMIDs to identify common pathways between them. We used the common pathways and publicly available drug-gene network to identify promising drug repurposing targets. ResultWe found CD4+Treg, CD4+Th1, and NK cells as top DACs in the inflammatory arthritis such as ankylosing spondylitis (AS), psoriatic arthritis, and rheumatoid arthritis (RA); neutrophils, granulocytes and BDCA1+CD14+ cells in systemic lupus erythematosus and systemic scleroderma; ILC2, CD4+Th1, CD4+Treg, and NK cells in the inflammatory bowel diseases (IBDs). We identified lymphoid cells (CD4+Th1, CD4+Treg, and NK) and their associated pathways to be important in HLA-B27 type diseases (psoriasis, AS, and IBDs) and in primary-joint-inflammation-based inflammatory arthritis (AS and RA). Based on the common cellular mechanisms, we identified lifitegrast as potential drug repurposing candidate for Crohns disease, and other IMIDs. ConclusionOur method identified top DACs, DAGs, common pathways, and proposed potential drug repurposing targets between IMIDs. To extend our method to other diseases, we built the DIME tool. Thus paving way for future (pre-)clinical research.
- organism: human
- assay: bulk RNA-seq
- research focus: cell type annotation
- research focus: differential expression
- research focus: drug response / drug discovery
- approach: statistical model
- Citations
- 1
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- scDrugPrio: A framework for the analysis of single-cell transcriptomics to address multiple problems in precision medicine in immune-mediated inflammatory diseases
S. Schaefer, M. Smelik, … M. Benson·bioRxiv·Nov 8, 2023
- Integrative computational approach identifies new targets in CD4+ T cell-mediated immune disorders
Bhanwar Lal Puniya, Rada Amin, … Tomáš Helikar·npj Systems Biology and ApplicationsPeer-reviewed·Jan 22, 2021
- Integrative Mendelian Randomization approaches for therapeutic target prioritisation in immune-mediated diseases
Maria K. Sobczyk, Tom R. Gaunt·Scientific ReportsPeer-reviewed·Mar 3, 2026
- A longitudinal single-cell therapeutic atlas of anti-tumour necrosis factor treatment in inflammatory bowel disease
T. Thomas, C. Rich-Griffin, … C. Buckley·bioRxiv·May 5, 2023
- Immune disease variants modulate gene expression in regulatory CD4+ T cells and inform drug targets
Lara Bossini‐Castillo, Dafni A. Glinos, … Gosia Trynka·bioRxiv·May 31, 2019
- immuneKG: An Immune-Cell-Aware Knowledge Graph Framework for Target Discovery in Immune-Mediated Diseases
Yaowen Ye·bioRxiv·May 7, 2026